Business Context and Reporting Period
This Form 8-K was filed by Palisade Bio, Inc. on November 23, 2022, reporting events that occurred on November 17, 2022. The filing focuses on a key executive appointment rather than periodic financial results.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to executive compensation:
- Compensation: Dr. Herbert Slade will be compensated $240,000 per annum for his role as Chief Medical Officer.
Material Changes
The primary material change reported is the appointment of Dr. Herbert B. Slade as Chief Medical Officer. Key details include:
- Role: Chief Medical Officer (part-time consultant basis).
- Effective Date: November 17, 2022.
- Background: Dr. Slade has over 25 years of experience in pharmaceutical and medical device industries, including prior CMO roles at Smith & Nephew and DFB Pharmaceuticals.
- Terms: The arrangement does not include severance or termination-based benefits.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or specific risk factors. Management commentary is limited to the announcement of Dr. Slade's appointment and his professional qualifications. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the terms of the amended and restated consulting agreement to be entered into with Dr. Slade.
- Review the attached press release (Exhibit 99.01) for additional context on the appointment.
- Check subsequent filings for updates on the company's clinical development pipeline, as this filing does not address operational progress.